Abstract
Previous studies by us demonstrated that radiation induces tumor neoantigen presentation on cell surface Class I MHC, increases expression of death receptors (FAS and CD40) and translocation of cytoplasmic stress proteins (calreticulin, HSP70) to the cell surface as “danger signals” for dendritic cell activation. Therefore, we hypothesized that radiation therapy (RT) would amplify the immune response to a conventional tumor vaccine. In this study, we examine whether RT can amplify the immune response to PSA following an attenuated Listeria-based PSA vaccine (ADX-142, Advaxis, NJ) designed for immunotherapy of PC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
